Aurora a kinase inhibitor vic 1911

Drug Overview

Aurora A kinase inhibitor vic 1911 is an experimental medical treatment known as a Targeted Therapy or a “Smart Drug.” Unlike traditional chemotherapy, which can damage many types of cells in the body, smart drugs are designed to find and block specific proteins that help cancer cells grow and multiply. VIC-1911 belongs to a specific group of medicines called kinase inhibitors.

Currently, VIC-1911 is an investigational drug. This means it is still being tested in clinical trials to see if it is safe and effective. It is not yet available at standard pharmacies. Doctors are primarily studying this drug for use in patients with advanced solid tumors, especially lung cancer and certain types of breast cancer.

• Generic Name: VIC-1911 (also known as an Aurora A Kinase Inhibitor)
• US Brand Names: None (Currently investigational)
• Drug Class: Aurora A Kinase Inhibitor / Targeted Therapy
• Route of Administration: Oral (taken by mouth as a tablet or capsule)
• FDA Approval Status: Not FDA Approved; currently in Phase I and Phase II clinical trials.
  
  Read about the targeted aurora a kinase inhibitor vic 1911. Our dedicated specialists provide compassionate care and advanced oncology therapies.

What Is It and How Does It Work? (Mechanism of Action)

To understand how VIC-1911 works, think of a cancer cell as a building under construction. Every time a cancer cell divides into two new cells, it needs a specialized “construction crew” to organize its DNA. A protein called Aurora A Kinase acts as the foreman of this crew. It helps build the scaffolding (called the mitotic spindle) that pulls the DNA apart so the cell can successfully split.

At the molecular level:

VIC-1911 is designed to enter the cancer cell and lock onto the Aurora A Kinase protein. By binding to this protein, the drug stops the “construction crew” from doing its job.

1. Blocking the Scaffold: When VIC-1911 blocks Aurora A, the cell cannot build the scaffolding needed to move its DNA.
2. Cell Cycle Arrest: The cell realizes something is wrong and stops its growth process in a stage called mitosis.
3. Apoptosis (Cell Death): Because the cell cannot divide properly, it eventually triggers a self-destruct signal. This leads to the death of the cancer cell without affecting as many healthy, non-dividing cells.

By targeting this specific pathway, researchers hope VIC-1911 can shrink tumors that have become resistant to other treatments.

FDA Approved Clinical Indications

Important Note: VIC-1911 is an experimental drug and does not have official FDA approval for general public use yet. It is currently being studied for the following:

Oncological Uses (Investigational):

• Non-Small Cell Lung Cancer (NSCLC): Specifically for patients with certain genetic markers like MYC mutations.
• Small Cell Lung Cancer (SCLC): Used alone or in combination with other drugs.
• Advanced Solid Tumors: For cancers that have spread to other parts of the body and have not responded to standard therapy.
• Triple-Negative Breast Cancer: Investigated for its ability to stop aggressive cell division.

Non-oncological Uses:

• There are currently no non-cancer uses for this medication.

Dosage and Administration Protocols

Because VIC-1911 is still in the testing phase, the exact “standard” dose is being determined by clinical researchers. The doses listed below are examples of what has been used in recent clinical studies.

Dose Adjustments

• Hepatic (Liver) Insufficiency: Since the liver processes this medication, doctors monitor liver enzymes closely. If liver tests become too high, the dose may be lowered or paused.
• Renal (Kidney) Insufficiency: Current studies are still gathering data on how the kidneys handle this drug. Patients with kidney issues are monitored for signs of drug buildup in the blood.

Clinical Efficacy and Research Results

Recent clinical research from 2020 to 2025 has focused on how VIC-1911 performs when combined with other treatments like chemotherapy.

• Combination with Taxanes: Studies have shown that VIC-1911 may make certain chemotherapies (like paclitaxel) work better. In early trials, some patients whose cancer had stopped responding to chemo saw their tumors shrink again when VIC-1911 was added.
• Tumor Shrinkage: In Phase I dose-finding studies, researchers observed a “Disease Control Rate” (where the cancer either shrank or stayed the same size) in approximately 40% to 50% of patients with very advanced solid tumors.
• Genetic Targeting: Data suggests that tumors with high levels of a protein called MYC respond better to VIC-1911. Patients with these specific “biomarkers” may see better results than the general population.

Safety Profile and Side Effects

Because VIC-1911 affects cell division, it can impact healthy cells that divide quickly, such as blood cells and the lining of the stomach.

Warning Information

There is currently no Black Box Warning for VIC-1911 because it has not yet been approved for commercial sale.

Common Side Effects (>10%)

• Neutropenia: A drop in white blood cells, which can make it easier to get an infection.
• Fatigue: Feeling very tired or having low energy.
• Nausea and Diarrhea: General stomach upset.
• Alopecia: Thinning hair or hair loss (often milder than standard chemotherapy).
• Mouth Sores (Mucositis): Pain or redness in the mouth.

Serious Adverse Events

• Febrile Neutropenia: A fever occurring when white blood cell counts are very low (this is a medical emergency).
• Severe Dehydration: Often caused by unmanaged diarrhea or vomiting.
• Liver Enzyme Elevation: Significant stress on the liver (detected through blood tests).

Management Strategies

• For Low Blood Counts: Doctors perform frequent blood tests. If counts are too low, they may give “growth factor” shots to help the body make more white blood cells.
• For Mouth Sores: Patients are encouraged to use a soft toothbrush and avoid spicy or acidic foods.

Research Areas

VIC-1911 is a key part of research into Synthetic Lethality. This is a strategy where scientists find a cancer cell’s “weak spot” and use a drug to knock out its last remaining backup system. Current research is exploring how VIC-1911 can be used alongside Immunotherapy. The goal is to see if VIC-1911 can break down the cancer cells in a way that makes them easier for the body’s natural immune system to find and destroy.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed

• Complete Blood Count (CBC): To check baseline levels of white and red blood cells.
• Liver Function Test: To ensure the liver is healthy enough to process the drug.
• Tumor Biopsy/Biomarker Testing: To see if the cancer has the specific MYC proteins that VIC-1911 targets.

Precautions During Treatment

• Infection Risk: Wash your hands often and avoid large crowds or people who are sick, especially during the “7 days on” portion of your treatment.
• Contraception: This drug can harm an unborn baby. Both men and women should use effective birth control during and for several months after treatment.

“Do’s and Don’ts”

• DO take the medication at the same time every day to keep levels steady in your blood.
• DO tell your doctor immediately if you develop a fever of 100.4°F (38°C) or higher.
• DON’T stop taking the medication without talking to your clinical trial team first.
• DON’T eat grapefruit or drink grapefruit juice, as it can interfere with how the drug is absorbed by your body.

Legal Disclaimer

This guide is for informational purposes only and does not constitute medical advice. VIC-1911 is an investigational drug and is not currently FDA-approved for commercial use. It should only be used under the supervision of a qualified oncologist within a clinical trial setting. Always consult your healthcare provider regarding any questions about a medical condition or treatment. As research is ongoing, ensure you discuss the most up-to-date data with your oncology team.